Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer? By Potosky et al. 2014
Concluding summary from the paper: “[Potosky et al.] found no mortality benefit from primary androgen deprivation therapy compared with no primary androgen deprivation therapy for most men with clinically localized prostate cancer who did not receive intent therapy.”
For the full abstract, see: http://www.ncbi.nlm.nih.gov/pubmed/24638009
Commentary: Androgen deprivation improves the quality of life of advanced prostate cancer patients who have symptoms (for example bone pain) from their cancer, but does it extend life if used earlier to treat asymptomatic rises in PSA when there is no indication of metastatic disease? Potosky et al. explored this question by analyzing data in the HMO Cancer Research Network. Their retrospective look of the records from 15,170 patient shows that primary androgen deprivation therapy does not reduce risk of all-cause mortality (dying from any cause, not just cancer) for men with clinically localized prostate cancer.
Potosky AL, Haque R, Cassidy-Bushrow AE, Yood MU, Jiang M, Tsai H-T, Luta G, Keating NL, Smith MR, Van Den Eeden SK. 2014. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer? Journal of Clinical Oncology. 2014 March 17 [Epub ahead of print]